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Abstract
Background: Since the breast cancer screening programme in the Basque Country (BCSPBC) was started in 1996, more
than 400,000 women aged 50 to 69 years have been invited to participate. Based on epidemiological observations and
simulation techniques it is possible to extend observed short term data into anticipated long term results. The aim of
this study was to assess the effectiveness of the programme through 2011 by quantifying the outcomes in breast cancer
mortality, life-years gained, false positive results, and overdiagnosis.
Methods: A discrete event simulation model was constructed to reproduce the natural history of breast cancer
(disease-free, pre-clinical, symptomatic, and disease-specific death) and the actual observed characteristics of the
screening programme during the evaluated period in the Basque women population. Goodness-of-fit statistics were
applied for model validation. The screening effects were measured as differences in benefits and harms between the
screened and unscreened populations. Breast cancer mortality reduction and life-years gained were considered as
screening benefits, whereas, overdiagnosis and false positive results were assessed as harms. Results for a single cohort
were also obtained.
Results: The screening programme yielded a 16 % reduction in breast cancer mortality and a 10 % increase in the
incidence of breast cancer through 2011. Almost 2 % of all the women in the programme had a false positive result
during the evaluation period. When a single cohort was analysed, the number of deaths decreased by 13 %, and 4 %
of screen-detected cancers were overdiagnosed. Each woman with BC detected by the screening programme gained
2.5 life years due to early detection corrected by lead time.
Conclusions: Fifteen years after the screening programme started, this study supports an important decrease in breast
cancer mortality due to the screening programme, with reasonable risk of overdiagnosis and false positive results, and
sustains the continuation of the breast cancer screening programme in the Basque population.
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Background
Breast cancer (BC), as a disease, meets the criteria neces-
sary for carrying out a population-based screening [1].
The main objective of screening for BC seems as simple as
advancing the time of diagnosis and treating the cancer in
earlier stages to reduce breast cancer specific mortality.
Indeed, overall survival would also increase due to avoided
breast cancer. However, although BC screening is bene-
ficial for some, it also may be harmful for others. First,
false positive results of mammography can lead to anx-
iety as they provoke episodes of stress. Second, some
women are diagnosed and treated for cancers that, in
the absence of screening, never would have become
symptomatic (i.e., overdiagnosis) [2].
In most developed countries BC screening is a well-
established preventive intervention. Many western European
countries implemented mammography screening on the
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basis of several randomised trials initiated in the 1970s that
showed a statistically significant reduction in mortality rates
in screened women aged 50 and older [3, 4]. The Health De-
partment of the Basque Government launched the screening
programme in 1996, and it was extended to all women aged
50 to 64 years during 1997 and 1998. The decision was held
on general recommendations, but there was not informed
evidence on its long term impact on the Basque women
population with its specific epidemiological characteristics.
The BC screening programme in the Basque Country
(BCSPBC) has invited more than 400,000 women since
1996. The risk factor profile of the Basque women popula-
tion would be similar to the screened women population
in Catalonia described by Arrospide et al. [5].
Doubts about the balance between screening benefits
and harms have increased in recent years [6, 7]. In fact,
the Swiss Medical Board published a report in 2013
recommending that systematic mammography screen-
ing programmes in which the target population is in-
vited periodically from a population based organisation,
should not be introduced and a dead line should be set
on existing programmes [8, 9]. The decision regarding
continuation of screening should be taken on the basis
of the data regularly collected and monitored in local
screening programmes, with proper statistical analysis,
in addition to the results from the randomized trials
[10]. Mathematical models based on the natural history
of BC can be helpful to translate those short-term evi-
dence data into long-term health outcomes in order to
assess and improve the performance of the programme
[11, 12]. Actually, classical methodologies, such as ran-
domised trials, pose major limitations in assessing the
long-term effects that are the key outcomes when evaluat-
ing health policies such as BC screening. However, those
long-term indicators are not considered in the quality in-
dicators proposed by the European Screening Guidelines
[13]. Nevertheless, it is possible to extend observed epi-
demiological short term data into anticipated long term
results based on simulation techniques. Several models
based on European data have been published [14–17], but
very few of those were used to assess the effect of an
established screening programme on a real, dynamic
population using a multi-cohort model including all the
observed cohorts at each time period [18].
The main objective of this study was to assess the
health benefit (mortality reduction) and harms (false
positive results and overdiagnosis) attributable to the
BCSPBC in Basque women since its implementation in
1996 through 2011.
Methods
A discrete event simulation model [19, 20] was built to
reproduce the natural history of BC for women invited
to participate in the programme and the characteristics
of the BCSPBC since its beginning in 1996 through 2011.
The screening programme comprised multiple cohorts of
women; a cohort was defined as a group of women invited
to participate for the first time in the screening programme
in a calendar year. Following the terminology used by Hoyle
and Anderson the cohort starting screening in the current
year is defined as the incident cohort, and those already
undergoing screening from previous years are known as
the prevalent cohorts [21]. These terms do not correspond
to any disease state in this context but to screening eligibil-
ity. Our model reproduced the entire female population in-
vited into the programme during the period 1996–2011.
Multiple cohort models, also known as dynamic population
models, are used to represent the whole women population
that have been invited to the program during the study
period whereas single cohort models are useful to conclude
lifetime effects in a woman with specific characteristics.
A simplified diagram of the model is shown in Fig. 1 and
the data used to implement it is specified in the additional
data reported (see Additional file 1: Table S1). The simula-
tion model was constructed using Arena simulation soft-
ware (Version 14.0, Rockwell software, Milwaukee, WI). No
ethical approval or consent was required as no experi-
mental research on humans was involved in this study.
However, the Ethics Committee for Clinical Research in
Gipuzkoa Health Area evaluated and approved the study.
Simulated population
The exact number of women invited to participate in
the programme for the first time and their ages at that
time were available from the programme database. Exactly
414,041 life histories were created, one for every woman
invited at least once into the BCSPBC from 1996 through
2011 (see Additional file 1: Table S2).
The age distribution of the invited women changed
during the study period. From 1996 to 1998 during the
programme implementation, the population consisted
only of the incident cohorts aged 50 through 64 years.
In subsequent years, instead, the incident cohort in-
cluded those aged 50 to 51 years. Actually, the target
population also included several prevalent cohorts, apart
from the incident cohort. The extension of the target
population from 50 to 64 years and then 50 to 69 years
began in 2006, with women aged 65 years continuing in
the programme until age 69.
Mortality from causes other than BC was randomly
assigned, depending on the woman’s birth cohort, based
on an empirical function. All-cause and BC-caused mortal-
ity data were obtained from the Basque mortality registry
for the period 1986–2010 (see Additional file 1: Table S1).
The high quality of the Basque cancer registry data has
been demonstrated by Izarzugaza et al. [22]. The Basque
Statistics Institute (EUSTAT) provided the population
of Basque women by age and birth cohort. We applied
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an actuarial method that removes breast cancer as a
cause of death to estimate the age at death from causes
other than BC, by birth cohort [23].
Natural history
We modelled the natural history of BC using the ap-
proach adopted by Lee et al. [24]. Four main states of
health were distinguished: (1) disease-free or undetect-
able BC; (2) asymptomatic BC that can be diagnosed by
screening or preclinical phase; (3) symptomatic BC diag-
nosed clinically; and (4) death from BC.
The age distribution used to assign the onset of the
preclinical phase was obtained from Rue et al. [25]. On
the basis of BC incidence from Catalan cancer registries
and a distribution of the sojourn time or duration in the
pre-clinical state, those authors used a generalized linear
model with a Poisson distribution and a polynomial
parameterization for the variables of age and cohort for
the estimation of BC incidence when no data was available
[25]. Cohort effects enabled including upward breast can-
cer incidence trends in our model. We assumed, as did
Lee et al., that the sojourn time of the pre-clinical phase
follows an exponential distribution as based on results of
clinical trials [24]. The mean value used by Lee et al. for
women aged 50 years or more was 4 years.
One of the main assumptions in this model was that
every woman who reached the clinical state would be di-
agnosed clinically at the beginning of this state. Thus, we
used the age-specific distribution of BC detection stages
observed in the cancer registries of the Basque Country in
1995, before the screening programme began for clinically
detected BC (see Additional file 1: Table S3). In situ car-
cinomas are also included in the model as the lowest stage
in which BC could be detected. On the basis of the work
by Vilaprinyó et al. [26], we applied distributions of age-
and stage-specific survival in women diagnosed either
clinically or by screening. Thus, each diagnosed woman
was assigned two ages at death and the minimum of
these two ages determined the cause and age of death
for each woman. Clinical practice and treatments used
in detected breast cancers during the studied period
followed European guidelines and were described in de-
tail by Arrospide et al. [27].
Screening effects
The screening test for BCSPBC consisted of mammog-
raphy with double projection (cranio-caudal and oblique
lateral view) carried out biennially [28]. The total number
of mammograms performed in the programme was deter-
mined by the number of invited women (including early
recalls) and annual attendance rates, which were exactly
known from the programme data base (see Additonal file
1: Table S2). Annual attendance rates were considered in-
dependent as correlation of the participation in first and
repeated screening rounds was not available.
Sensitivity and specificity of the entire early detection
programme, as well as distribution of breast cancer stage
for cancers detected by screening, varied during the study
period. Four phases were distinguished: (1) from 1996 to
1999, the implementation phase, when most of the women
Fig. 1 Simplified diagram of the model. Detailed legend: Simplified diagram of the simulation model used to reproduce the natural history of breast
cancer for women invited to participate in the programme and the characteristics of the Breast Cancer Screening Programme in the Basque Country
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invited into the programme were incident; (2) from
2000 to 2005, the prevalence phase, when the percent-
age of women invited for the first time was much lower
than the percentage of women invited for successive
mammograms; (3) from 2006 to 2008, extension phase,
when the programme was extended to women aged 65
to 69 years; (4) from 2009 to 2011, digital phase, when
the switch to digital mammography occurred. Sensitiv-
ity and specificity of the screening programme for each
of the defined phases was calculated on the basis of
observed mammography results in the BCSPBC, to-
gether with the number of invited women and number
of screening-detected breast cancers and observed interval
cancers (see Additional file 1: Table S4). In the model, a
positive or negative screening result was assigned based on
the presence or absence of BC in each woman and the cor-
responding sensitivity and specificity of the programme.
Distributions of disease stages for screening-detected
cases were also obtained for the different phases of
BCSPBC (implementation, prevalence, extension and
digital) with use of observed data from the screening
programme (see Additional file 1: Table S3). This figures
were in line with other stage distributions used in similar
studies carried out in different countries [17, 24]. In each
woman the same random number as the one used for clin-
ical detection stage assignment was used to simulate the
stage distribution for screening-detected cancers, in order
to estimate the advance in detection stage due to screening.
Model validation
The model was run in the screened scenario for the whole
female population invited at least once into the BCSPBC
during the study period in order to reproduce the actual
performance of the programme. Model calibration and
validation procedure is fully described in the additional file
(see Additional file 1). Three main parameters were cali-
brated: time between consecutive invitations, age distribu-
tion of preclinical phase onset and its mean duration. We
obtained the best fitting parameters to include in the final
model by following the seven-step approach for calibrat-
ing models suggested by Karnon et al. [29] and detailed in
the additional file (see Additional file 1).
Screened versus unscreened scenario: outcomes analysis
When the model for the screened scenario was cali-
brated and validated the same model was run also for
the unscreened scenario involving the same female
population invited at least once into the BCSPBC during
the study period. All the created entities were cloned to ob-
tain two identical populations (screened and unscreened)
in each run.
We first used a multi-cohort model that allowed the
best approach to reproduce population dynamics in the
Basque Country as well as the natural history of breast
cancer. However, the assessment of the balance between
benefits and harms from preventive programmes typic-
ally requires a long follow-up thus the key for its inter-
pretation is to achieve the steady state that is defined as
the time when each recently observed behaviour of the
system will remain constant in the future [30]. As the
first 15 years of the BCSPBC evaluated in this study
were not enough to achieve this state, we cannot ensure
that the differences between the two scenarios estimated
in 2011 will remain in the future.
To further understand the effects of a programme that
requires long-term follow-up, we reran the model using
a single cohort of 50,000 women aged 50 years who were
invited into the programme for the first time in 1996, as-
suming 100 % participation and life-time follow-up [31].
The inputs used to extrapolate the results from 2011 on
were based on the same parameters as those that were
used for 2011.
In order to include variability of population character-
istics in the model, the multi-cohort model was run
1,000 times. Mean and standard deviations for the re-
sults of the 1,000 replications were calculated. The same
outputs were obtained for both multi-cohort and single-
cohort model. The multi-cohort model was used to
estimate population-level effects, whereas individual
benefits and harms were estimated with the same model
for a single cohort.
The estimated age-specific BC incidence and mortality
during the period 1996–2011, which was a scenario that
fit the actual development of the screening programme,
was compared with the simulated scenario without screen-
ing. Overdiagnosis is defined as the number of women
who are diagnosed and treated for cases of breast cancer
that never would have become symptomatic in the absence
of screening. However, the operational definition in the
literature used to estimate overdiagnosis is the difference
between the number of BC cases detected with screening
and the number without screening. In our case as steady
state is not achieved, this definition to estimate overdiagno-
sis includes not only overdiagnosis but also screen detected
BC cases that would be clinically detected in the future in
absence of screening [32]. Therefore, overdiagnosis is
overestimated when analysing population level results
in a multi-cohort model that did not achieve the steady
state. Accordingly, we will refer in this case to the "inci-
dence increase" instead of "overdiagnosis".
In the case of a single cohort with lifetime follow-up,
however the definition used to estimate the incidence in-
crease matches exactly with overdiagnosed cases of BC. We
first calculated the relative BC incidence increase (i.e., over-
diagnosis) compared with the number of BC cases in a sce-
nario without screening [33] and in a second approach, we
estimated the fraction of overdiagnosed cases of BC identi-
fied by the screening programme.
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In addition, the number of women with a false positive
result who were referred to the reference hospital for add-
itional tests based on the sensitivity and specificity data
from the BCSPBC were also considered harms of the
screening programme.
The probabilities of BC-related death in women de-
tected in the screened and unscreened cohorts were ana-
lysed with Cox regression only for the single-cohort
analysis. Survival time was measured from the beginning
of the assigned clinical phase even for BC detected by
screening in order to avoid lead time bias.
Results
Table 1 presents the main population-level results (multi-
cohort model) of this evaluation in terms of BC incidence
and mortality rates per 100,000 women. BC incidence
rates for the age groups in the screening programme were
calibrated; thus, goodness of fit between the modelled
Table 1 Evolution of estimated breast cancer incidence and mortality rates per 100,000 women in year 2000, 2005 and 2011
In year 2000 In year 2005 In year 2011
BC incidence Mean 95 % CI Mean 95 % CI Mean 95 % CI
Screened population
<55 316.9 (260.4, 373.4) 285.6 (239.4, 331.8) 310.2 (266.4, 354.0)
55-59 168.9 (138.9, 198.8) 214.9 (181.1, 248.6) 245.9 (209.9, 281.9)
60-64 220.5 (180.6, 260.2) 216.9 (182.0, 251.7) 276.1 (237.0, 315.1)
65-69 162.6 (129.2, 196.0) 199.7 (161.4, 237.8) 264.7 (227.0, 302.3)
70-74 0 (0.0, 0.0) 201.3 (163.3, 239.2) 251.2 (206.4, 295.9)
75-79 0 (0.0, 0.0) 0 (0.0, 0.0) 300.2 (253.5, 346.8)
> = 80 0 (0.0, 0.0) 0 (0.0, 0.0) 94.9 (11.7, 178.1)
Unscreened population
<55 180.2 (137.7, 222.7) 188 (150.5, 225.3) 206.7 (171, 242.3)
55-59 154.5 (125.9, 183.1) 190.8 (159, 222.5) 216.2 (182.4, 249.8)
60-64 204.7 (166.4, 242.9) 200.1 (166.6, 233.4) 249 (211.9, 285.9)
65-69 190.6 (154.4, 226.6) 246.3 (203.9, 288.6) 238.4 (202.7, 273.9)
70-74 0 (0.0, 0.0) 227.2 (186.8, 267.4) 295.9 (247.4, 344.4)
75-79 0 (0.0, 0.0) 0 (0.0, 0.0) 305.8 (258.6, 352.8)
> = 80 0 (0.0, 0.0) 0 (0.0, 0.0) 94.9 (11.7, 178.1)
BC mortality
Screened population
<55 5.2 NA 7.8 (0.1, 15.3) 11.3 (2.9, 19.5)
55-59 8.3 (1.6, 14.9) 27.6 (15.4, 39.6) 35.7 (21.9, 49.4)
60-64 11.2 (2.2, 20.1) 36.4 (22.1, 50.6) 53.2 (36.0, 70.3)
65-69 12.5 (3.2, 21.7) 49.4 (30.4, 68.4) 57.1 (39.6, 74.6)
70-74 0 (0.0, 0.0) 65.2 (43.6, 86.8) 95.5 (67.8, 123.0)
75-79 0 (0.0, 0.0) 0 (0.0, 0.0) 130.3 (99.5, 161.0)
> = 80 0 (0.0, 0.0) 0 (0.0, 0.0) 38 NA
Unscreened population
<55 10.4 (0.2, 20.6) 13.6 (3.5, 23.6) 17.6 (7.2, 28.0)
55-59 12.4 (4.3, 20.5) 37.1 (23.0, 51.0) 45.1 (29.7, 60.5)
60-64 18.6 (7.0, 30.1) 47.8 (31.5, 64.1) 65.8 (46.7, 84.8)
65-69 19.6 (8.0, 31.1) 64.4 (42.7, 86.0) 74.8 (54.8, 94.7)
70-74 0 (0.0, 0.0) 74.5 (51.4, 97.5) 115.9 (85.5, 146.2)
75-79 0 (0.0, 0.0) 0 (0.0, 0.0) 132.1 (101.1, 163.0)
> = 80 0 (0.0, 0.0) 0 (0.0, 0.0) 38 NA
BC Breast cancer, CI Confidence interval, NA Not applicable
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incidence rates and observed rates was acceptable based
on the chi-square test. Compared with the scenario with-
out screening, by 2011, the incidence for women aged 50
to 54 years increased by almost 50 % in the scenario with
screening, whereas the incidence in age groups between
55 and 69 years increased more than 10 %. For women
aged 70 to 74 years, BC incidence decreased by 15 %
because of screening in younger ages. The accumulated
increase in BC detection attributable to the screening
programme from 1996 to 2011 was 17.0 % (Table 2). The
extension of the programme to women 69 years of age
had a big impact in this figure as, in 2005 alone, before
the programme was extended, the increase in diagnosed
BC cases was 6.3 %, whereas using data from 2011, the in-
crease in BC incidence rose to 10.2 % (Fig. 2).
Among 1,308,030 mammograms performed in the
BCSPBC during the evaluated period, 13,478 women
with positive mammograms were referred for additional
testing at the reference hospital during the study period;
39.1 % of them were diagnosed with BC (Table 2).
Reduction in mortality was greater the more cohorts
were included in the programme. During the study period
(1996–2011), the screening programme avoided 19.7 % of
the deaths due to BC that would have occurred in a sce-
nario without screening (Table 2). Specifically in 2011, the
BC mortality rate in women invited into the screening
programme was 16.0 % lower than in a scenario without
screening (Fig. 3). The screening effect on BC mortality in
2011 was greater for women aged 50 to 55 years, with a
27.3 % decrease than for the rest of the age groups in the
screening programme (55–69 years) with a 22.2 % decrease.
Women aged 70 or more who previously participated in
the programme still had a significant decrease in their
probability of death from BC (17.5 % for women aged
70–74 years and 2.8 % for women aged 75–79), com-
pared with the scenario without screening (Table 1).
When we analysed the survival time, corrected by lead
time, for screening-detected BC cases in a single cohort
with lifetime follow-up, the hazard ratio for BC mortality
was 0.83 (95 % confidence interval [CI], 0.77-0.89) (Fig. 4).
Life-years gained were 32.6 days for each woman invited
into the screening programme and 2.5 years gained for each
woman with BC detected by the screening programme
(Table 3). In this scenario, 1 out of 28 women detected with
BC by screening (3.6 %) would be overdiagnosed (Table 3).
The mean lead time in BC detection produced by the
screening programme, excluding overdiagnosed cases,
was 3.2 years (95 % CI, 3.1-3.4).
Discussion
Our main finding was that the BCSPBC achieved an im-
portant reduction in population level BC mortality in 2011
(16.0 %), with limited adverse effects. Therefore, our results
support the continuation of the programme as a public pol-
icy aimed at reducing the burden of BC in the Basque
population. The estimations for 2011 in terms of BC inci-
dence increase and false positive results were in line with
the values described in the literature [2, 33–36]. Planning a
population-level breast cancer screening programme can
require multiple criteria for decision making; it involves
primarily reduction in BC mortality rates, but it also needs
to minimize overdiagnosis and false positive events. In our
case, as the screening programme was already implemented
and the mathematical model was used for evaluation,
Table 2 Accumulated population level results for the period from 1996 to 2011. Detailed legend: Main accumulated results for the period
from 1996 to 2011 in the analysis of the multi-cohort model reproducing the population of Basque women invited into the breast cancer
screening programme
Screened population Unscreened population
Mean 95 % CI Mean 95 % CI
Number of women 411,782 (411,619, 411,945) 411,782 (411,619, 411,945)
Participation rate 77.80 % (77.6 %, 77.9 %) 0 % (0.0 %, 0.0 %)
Number of mammograms 1,308,030 (1,304,309, 1,311,750) 0 (0, 0)
False positive results 8,211 (7,876, 8,546) 0 (0, 0)
False positive/women 1.99 % (1.91 %, 2.08 %) - -
False positive/mammography 0.63 % (0.60 %, 0.65 %) - -
Screening-detected BC 5,267 (4,999, 5,535) 0 (0, 0)
Total detected BC 10,021 (9,644, 10,399) 8,567 (8,215, 8,918)
Difference in BC detection 1,454 (1,316, 1,593) - -
Increase in BC detection - - 17.0 % (15,2 %, 18,8 %)
BC deaths 1,512 (1,370, 1,655) 1,883 (1,725, 2,041)
Difference in BC deaths - - 371 (299, 442)
Difference in BC deaths/BC deaths - - 19.7 % (16.3 %, 23.1 %)
BC Breast cancer, CI Confidence interval
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decision makers' preferences should be considered in
the interpretation of the results as no unique optimal
solution exists [37].
Evaluating screening health effects is complicated as
we are analysing a system in which the natural history of
BC and screening effects are combined. To correctly in-
terpret its impact we should ensure that the measured
effects will remain steady in the future; otherwise its evalu-
ation could be misleading. The changes in screening fea-
tures, such as the extension implemented in 2006, modified
the evolution of the indicators (i.e. difference in BC inci-
dence) which hamper analysis of the screening programme.
Our results highlight that the variability between the results
from different studies depends primarily on the characteris-
tics of the screening programme, but it also depends on the
actual variation of these features during its implementation.
Therefore, we determined the estimated effects using the
model for a single cohort as complementary results.
Mortality results are in accordance with the population
level results obtained by The Cancer Intervention and
Surveillance Modeling Network (CISNET), a consortium
of the National Cancer Institute. CISNET results showed
a reduction in BC mortality between 7.5 % and 22.7 % in
the United States using seven different models [38].
According to the review published by Broeders et al., the
mean European estimate of reduction in BC mortality is
Fig. 2 Impact of the screening programme on breast cancer incidence at the population level. Detailed legend: Number of breast cancers
detected each year in the invited population estimated using multi-cohort model for the scenarios with and without screening
Fig. 3 Impact of the screening programme on breast cancer mortality at the population level. Detailed legend: Annual number of deaths due to
breast cancer in the invited population estimated using the multi-cohort model for the scenarios with and without screening
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25 % to 31 % for invited women [39]. Furthermore, a
meta-analysis that included 11 randomized controlled
trials with 13 years of follow-up estimated a 20 %
reduction in BC mortality (95 % CI 11 %-27 %) [34].
Specifically, in a study carried out in Spain using
mathematical models, Carles et al. concluded a 19.6 %
reduction in BC mortality, similar to our final estimate
[40]. When a single cohort (50 years old women in-
vited for the first time in 1996) was analysed with life-
time follow up, we concluded that BC mortality
Fig. 4 Breast cancer survival analysis corrected by lead time bias. Detailed legend: Breast cancer survival curves corrected by lead time bias among
cases detected in women in a single cohort for the scenarios with and without screening
Table 3 Accumulated results for a single cohort of women aged 50 years from 1996 to 2011. Detailed legend: Main results of a single
cohort of women aged 50 years invited to participate in the Basque breast cancer screening programme for the first time in 1996
Screened population Non-screened population
Mean 95 % CI Mean 95 % CI
Number of women 50,000 (50,000, 50,000) 50,000 (50,000, 50,000)
Screening age 50-69 years old - -
Participation rate 100 % 0 % (0.0 %, 0.0 %)
Number of mammograms 480,869 (480,150, 481,588) 0 (0, 0)
False positive results 3,151 (3,041, 3,260) 0 (0, 0)
False positive/women 6.3 % (6.1 %, 6.5 %) - -
False positive/mammography 0.7 % (0.6 %, 0.7 %) - -
Screen detected BC 1,776 (1,696, 1,856) 0 (0, 0)
Total detected BC 5,065 (4,926, 5,204) 5,001 (4,863, 5,139)
Difference in BC detection (Overdiagnosis) 64 (49, 79) - -
Increase in BC incidence - - 1.3 % (1.0 %, 1.6 %)
Overdiagnosis/Screening-detected BC 3.6 % (2.8 %, 4.4 %) - -
BC deaths 1,634 (1,556, 1,711) 1,880 (1,795, 1,964)
Difference in BC deaths - - 246 (215, 278)
Difference in BC deaths/BC deaths - - 13.1 % (11.6 %, 14.6 %)
Life years/women 82.6 (82.5, 82.7) 82.5 (82.4, 82.6)
Life years gained/women 0.09 (0.08, 0.10) - -
Life years gained/screen detected women 2.5 (2.2, 2.8) - -
BC Breast cancer, CI Confidence interval
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decreased by 13.1 %. Actually, 2.5 years of life were
gained for each woman with breast cancer detected by
the screening programme.
The Basque population had not arrived at a steady
state by 2011, and therefore, a longer follow-up is neces-
sary to estimate overdiagnosis at the population level
without overestimating it. When we assessed 10.2 % BC
incidence increase in 2011, we included early detected BC
cases although they were not necessarily overdiagnoses as
they could be detected from 2012 on. A study published by
Duffy et al. [41] concluded that a 15 % increase in incidence
in the screened group aged 50 to 69 years can persist
30 years after the start of the programme. In concordance,
at 29 years follow-up the long-term incidence of breast can-
cer in the Swedish Two-County Trial of Mammographic
screening, Yen et al. conclude that there was no excess of
incidence and thus, suggest that overdiagnosis is a minor
phenomenon [42].
Actually, when we analysed a single cohort of 50 years
old women followed until death, the estimated increase in
incidence was 1.3 % of the detected breast cancers com-
pared to a scenario without screening [32]. Gunsoy et al.
concluded that 5.6 % of all BC detected were overdiag-
nosed in a cohort of British women followed up from age
40 to 85 years [15]. The main difference with respect to
our 1.3 % of overdiagnosed cases might be due to the
mean sojourn time in the model of Gunsoy et al. When
Gunsoy et al. used a shorter sojourn time, overdiagnosis
decreased to 3.1 % of all BC diagnosed. Furthermore, as in
our model, the cohort was followed until death, the num-
ber of all BC detected increased, and therefore, the per-
centage was lower.
Although overdiagnosis could be considered the major
harm of screening, false positive mammographic results are
also important harms, since they can cause stress and a
decrement in quality of life in healthy women. Our single-
cohort analysis reported an accumulated risk of 6.3 % for a
false positive screening result, with early recall not included
as a positive result. False positive rates in our study were
concordant with a cumulative chance of 7.3 % estimated in
the Nijmegen population-based cohort study [36]. The lit-
erature review by Hofvind et al. [35] estimated that the risk
of an invasive procedure with benign outcome ranged from
1.8 % to 6.3 % per woman in Europe.
Strengths
Our study is strengthened by the exhaustive methodology
used for the validation process. The robustness of this
study is reinforced by the reproduction of the main results
obtained during the study period in the observed screened
population [43]. Thus, using the model, we were able to
estimate the results in a scenario without a screening
programme. The detailed mathematical model built to in-
clude the progressive dissemination of screening in all the
cohorts between 50 and 69 years of age enabled the inter-
pretation of the mortality reduction achieved in the first
15 years of the programme. Complementary single-cohort
analysis was also helpful when interpreting population
level effects.
Limitations
One limitation of this study was that it was built exactly for
the Basque women population invited to the BCSPBC from
1996 through 2011. However, using mathematical models
for the evaluation of an already implemented screening
programme is applicable to other populations.
A second limitation was that long-term follow-up made
it necessary to make assumptions for the projected years.
In this study the detection stage distribution of symptom-
atic BC from 2011 on was based on the same parameters
as in 2011.
Finally, it is worth mentioning that BC survival func-
tions applied in the simulation model relied on age and
stage at detection but did not change during the study
years. Consequently, the effect of improved treatment in
women with BC was not incorporated. This way we en-
sure the observed effect was of only related to screening.
Conclusions
In conclusion, this study has assessed the impact of the
BCSPBC at the population level in terms of reduction in
breast cancer mortality and the number of false positive
results and overdiagnosed cases. Fifteen years after the
screening programme started, this study supports an im-
portant decrease in breast cancer mortality, with reasonable
risk of harm with screening and sustains the continuation
of the breast cancer screening programme in the Basque
population. The analysis of the effects using the same simu-
lation model in a single cohort is complementary to the
population-level results and can help in the interpretation
of the population-level estimates.
Additional file
Additional file 1: Model inputs, calibration and validation. This file
includes model building details related to the simulation model developed
for the evaluation of the Breast Cancer Screening Programme in the Basque
Country. In particular, programme specific data used as inputs in the model,
a detailed description of the model calibration procedure and goodness-of-fit
of the final model are shown in this appendix. (PDF 88 kb)
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